(BDX) Becton Dickinson - Ratings and Ratios
Catheters, Syringes, Infusion, Diagnostics, Surgical
BDX EPS (Earnings per Share)
BDX Revenue
Description: BDX Becton Dickinson
Becton, Dickinson and Company (NYSE: BDX) is a diversified medical-technology firm that designs, manufactures, and markets a broad portfolio of products ranging from basic medical supplies (e.g., syringes, needles) to sophisticated diagnostic and interventional devices. Its customers span hospitals, physician offices, clinical laboratories, pharmaceutical manufacturers, and end-users worldwide, positioning the company as a core supplier across the healthcare value chain.
The business is organized into three operating segments. The **BD Medical** segment focuses on vascular access and infusion therapy, offering peripheral and central catheters, needle-free connectors, drug-transfer devices, and pharmacy automation solutions. The **BD Life Sciences** segment supplies specimen collection tools, automated culture and molecular testing platforms, flow cytometry instruments, and reagents for genomics and oncology applications. The **BD Interventional** segment delivers surgical and critical-care products, including hernia repair meshes, bio-resorbable grafts, infection-prevention solutions, and peripheral-intervention devices. These segments together generate roughly 55 % (Medical), 30 % (Life Sciences), and 15 % (Interventional) of total revenue, based on the latest segment reporting.
**Key performance indicators** (as of FY 2024) include: total revenue of $25.4 billion, a 6 % year-over-year increase driven primarily by strong demand for automated pharmacy systems and molecular diagnostics; an operating margin of 13.8 %, reflecting ongoing cost-discipline and scale efficiencies; and free cash flow of $2.9 billion, supporting a dividend yield of ~1.5 % and a share-repurchase program. **Sector drivers** such as an aging global population, rising hospital inpatient volumes, and accelerated adoption of point-of-care testing are expected to sustain demand for BDX’s product mix. Conversely, **macroeconomic uncertainties**-including potential supply-chain disruptions and fluctuating foreign-exchange rates-could pressure margins, especially in the capital-intensive Life Sciences segment.
For a deeper quantitative assessment of BDX’s valuation relative to peers, the ValueRay platform offers a granular, data-driven dashboard worth exploring.
BDX Stock Overview
| Market Cap in USD | 54,201m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1987-01-01 |
BDX Stock Ratings
| Growth Rating | -38.9% |
| Fundamental | 64.8% |
| Dividend Rating | 53.8% |
| Return 12m vs S&P 500 | -30.4% |
| Analyst Rating | 3.59 of 5 |
BDX Dividends
| Dividend Yield 12m | 2.18% |
| Yield on Cost 5y | 1.91% |
| Annual Growth 5y | 5.65% |
| Payout Consistency | 81.2% |
| Payout Ratio | 29.2% |
BDX Growth Ratios
| Growth Correlation 3m | 12.6% |
| Growth Correlation 12m | -71.5% |
| Growth Correlation 5y | -17.5% |
| CAGR 5y | -3.74% |
| CAGR/Max DD 3y (Calmar Ratio) | -0.09 |
| CAGR/Mean DD 3y (Pain Ratio) | -0.25 |
| Sharpe Ratio 12m | -0.33 |
| Alpha | -26.53 |
| Beta | 0.280 |
| Volatility | 20.68% |
| Current Volume | 1734.4k |
| Average Volume 20d | 1231.6k |
| Stop Loss | 185.2 (-3%) |
| Signal | 0.58 |
Piotroski VR‑10 (Strict, 0-10) 5.5
| Net Income (1.61b TTM) > 0 and > 6% of Revenue (6% = 1.28b TTM) |
| FCFTA 0.05 (>2.0%) and ΔFCFTA -1.15pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 3.91% (prev 28.25%; Δ -24.34pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.06 (>3.0%) and CFO 3.25b > Net Income 1.61b (YES >=105%, WARN >=100%) |
| Net Debt (18.61b) to EBITDA (4.80b) ratio: 3.87 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.10 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (288.7m) change vs 12m ago -0.54% (target <= -2.0% for YES) |
| Gross Margin 45.08% (prev 42.06%; Δ 3.02pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 38.71% (prev 35.67%; Δ 3.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 4.12 (EBITDA TTM 4.80b / Interest Expense TTM 613.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.92
| (A) 0.02 = (Total Current Assets 9.00b - Total Current Liabilities 8.16b) / Total Assets 54.90b |
| (B) 0.30 = Retained Earnings (Balance) 16.43b / Total Assets 54.90b |
| (C) 0.05 = EBIT TTM 2.53b / Avg Total Assets 55.24b |
| (D) 0.51 = Book Value of Equity 14.98b / Total Liabilities 29.43b |
| Total Rating: 1.92 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 64.80
| 1. Piotroski 5.50pt = 0.50 |
| 2. FCF Yield 3.50% = 1.75 |
| 3. FCF Margin 11.92% = 2.98 |
| 4. Debt/Equity 0.76 = 2.22 |
| 5. Debt/Ebitda 3.87 = -2.49 |
| 6. ROIC - WACC (= -0.76)% = -0.95 |
| 7. RoE 6.31% = 0.53 |
| 8. Rev. Trend 85.86% = 6.44 |
| 9. EPS Trend 76.50% = 3.83 |
What is the price of BDX shares?
Over the past week, the price has changed by +2.33%, over one month by +2.39%, over three months by +9.53% and over the past year by -18.93%.
Is Becton Dickinson a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of BDX is around 174.63 USD . This means that BDX is currently overvalued and has a potential downside of -8.57%.
Is BDX a buy, sell or hold?
- Strong Buy: 4
- Buy: 2
- Hold: 11
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the BDX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 208.3 | 9% |
| Analysts Target Price | 208.3 | 9% |
| ValueRay Target Price | 189.2 | -0.9% |
Last update: 2025-10-20 03:46
BDX Fundamental Data Overview
P/E Trailing = 34.6337
P/E Forward = 12.8205
P/S = 2.5344
P/B = 2.1559
P/EG = 0.9859
Beta = 0.28
Revenue TTM = 21.39b USD
EBIT TTM = 2.53b USD
EBITDA TTM = 4.80b USD
Long Term Debt = 17.53b USD (from longTermDebt, last quarter)
Short Term Debt = 1.81b USD (from shortTermDebt, last quarter)
Debt = 19.34b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 18.61b USD (from netDebt column, last quarter)
Enterprise Value = 72.79b USD (54.20b + Debt 19.34b - CCE 757.0m)
Interest Coverage Ratio = 4.12 (Ebit TTM 2.53b / Interest Expense TTM 613.0m)
FCF Yield = 3.50% (FCF TTM 2.55b / Enterprise Value 72.79b)
FCF Margin = 11.92% (FCF TTM 2.55b / Revenue TTM 21.39b)
Net Margin = 7.51% (Net Income TTM 1.61b / Revenue TTM 21.39b)
Gross Margin = 45.08% ((Revenue TTM 21.39b - Cost of Revenue TTM 11.74b) / Revenue TTM)
Gross Margin QoQ = 47.81% (prev 42.81%)
Tobins Q-Ratio = 1.33 (Enterprise Value 72.79b / Total Assets 54.90b)
Interest Expense / Debt = 0.79% (Interest Expense 152.0m / Debt 19.34b)
Taxrate = 18.35% (129.0m / 703.0m)
NOPAT = 2.06b (EBIT 2.53b * (1 - 18.35%))
Current Ratio = 1.10 (Total Current Assets 9.00b / Total Current Liabilities 8.16b)
Debt / Equity = 0.76 (Debt 19.34b / totalStockholderEquity, last quarter 25.47b)
Debt / EBITDA = 3.87 (Net Debt 18.61b / EBITDA 4.80b)
Debt / FCF = 7.30 (Net Debt 18.61b / FCF TTM 2.55b)
Total Stockholder Equity = 25.45b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.93% (Net Income 1.61b / Total Assets 54.90b)
RoE = 6.31% (Net Income TTM 1.61b / Total Stockholder Equity 25.45b)
RoCE = 5.88% (EBIT 2.53b / Capital Employed (Equity 25.45b + L.T.Debt 17.53b))
RoIC = 4.60% (NOPAT 2.06b / Invested Capital 44.82b)
WACC = 5.36% (E(54.20b)/V(73.54b) * Re(7.05%) + D(19.34b)/V(73.54b) * Rd(0.79%) * (1-Tc(0.18)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -100.0 | Cagr: -0.47%
[DCF Debug] Terminal Value 79.85% ; FCFE base≈2.82b ; Y1≈3.16b ; Y5≈4.20b
Fair Price DCF = 253.9 (DCF Value 72.77b / Shares Outstanding 286.6m; 5y FCF grow 13.83% → 3.0% )
EPS Correlation: 76.50 | EPS CAGR: 11.17% | SUE: 1.86 | # QB: 1
Revenue Correlation: 85.86 | Revenue CAGR: 5.45% | SUE: 0.36 | # QB: 0
Additional Sources for BDX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle